SOURCE: Pathway Medical

October 10, 2008 08:00 ET

Pathway Medical Technologies Demonstrates Commitment to Atherectomy Innovation at Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium

Pathway to Present Final Clinical Results for First-Generation Atherectomy Catheter Recently Cleared by the FDA for the Treatment of Peripheral Arterial Disease and Interim Study Data for Company's Next-Generation Device

KIRKLAND, WA and WASHINGTON, DC--(Marketwire - October 10, 2008) - 20th Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium -- Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral arterial disease (PAD), today announced that the company will present final data from Pathway's pivotal, multi-center European clinical trial for its first-generation device, the Pathway PV™ Atherectomy System, as well as interim study data for its next-generation device, at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium (TCT 2008), sponsored by the Cardiovascular Research Foundation (CRF). The data, presented by Dr. Thomas Zeller of Bad Krozingen in Germany and co-principal investigator of Pathway's clinical trials, demonstrate the safety and efficacy of Pathway's atherectomy catheter for the treatment of PAD in the lower limbs. In addition, Pathway will host a Breakfast Symposium providing an overview of the company's innovative technology. TCT 2008 takes place October 12-17, 2008 at the Washington Convention Center in Washington, D.C.

"TCT 2008 is where leading interventionalists from around the world gather to learn about state-of-the-art techniques to improve the lives of patients suffering from cardiovascular and endovascular disease and Pathway is proud to be part of the cutting-edge agenda," said Pathway President and CEO Paul Buckman. "Since receiving FDA clearance for the Jetstream™ Atherectomy Catheter in September, we have experienced tremendous interest in the technology from clinicians interested not only in minimally invasive treatment options for PAD patients, but also the benefits of a single device capable of treating an entire spectrum of disease. We firmly believe that the positive clinical findings from our pivotal trial in Germany and early results for our next-generation device will only reinforce that interest as we work towards changing the way PAD is treated in the U.S. and globally."

Pathway's activities at TCT 2008 include:

--  Oral Presentation -- TCT-81: "Percutaneous Rotational and Aspiration
    Atherectomy in Infrainguinal Peripheral Arterial Occlusive Disease:
    A Multicenter Study" presented by Dr. Thomas Zeller.
    What: Final results from Pathway's pivotal 172-patient European
    multi-center clinical trial completed in Germany at four primary
    centers: Abteilung Angiologie in Bad Krozingen, Germany, Hamburg
    University Cardiovascular Center in Hamburg, Germany, Clinical and
    Interventional Angiology, Heart Center-University of Leipzig in
    Leipzig, Germany, and DRK Kliniken in Berlin, Germany.
    When: Wednesday, October 15 at 10:35 a.m.
    Where: Washington Convention Center room 147AB.

--  Oral Presentation -- "Acute and Late Results of the European Pathway
    Trials in Native Peripheral Vessels and In-Stent Restenosis" presented
    by Dr. Thomas Zeller.
    What: Interim clinical study data for Pathway's next-generation device.
    When: Thursday, October 16 at 10:06 a.m.
    Where: Washington Convention Center room 147AB.

--  Breakfast Symposium -- "Strategies for Treating PAD: An Overview of the
    Pathway PV™  Atherectomy System" sponsored by Pathway Medical
    Technologies, Inc.
    What: A comprehensive overview of Pathway's atherectomy device,
    including case reviews and clinical data, with Drs. William A. Gray
    of New York-Presbyterian Hospital, Thomas M. Shimshak of St. Joseph
    Regional Medical Center in Milwaukee, and Thomas Zeller of Abteilung
    Angiologie in Bad Krozingen, Germany.
    When: Wednesday, October 15 at 7:00 a.m.
    Where: Washington Convention Center room 144C.

Pathway Medical Technologies, Inc. will exhibit at TCT 2008 in booth # 619 on the Second Level. Media interested in meeting with Pathway at the conference should contact Marisa Borgasano or Rebecca Phillips at Schwartz Communications, (415) 512-0770 or

About Jetstream™

The U.S. Food & Drug Administration (FDA) recently cleared the Jetstream™ Pathway PV™ Atherectomy System, a peripheral atherectomy catheter designed to remove artery-clogging plaque for patients suffering from PAD in the lower limbs. Jetstream™ is the first atherectomy device on the market capable of treating an entire spectrum of disease found in the PAD patient, including hard and soft plaque, calcium, thrombus and fibrotic lesions with consistent clinical results. Jetstream™ boasts an expandable cutting tip with rotating blades that safely debulk and preemptively remove plaque through continual aspiration to minimize the risk of distal embolization. Jetstream™ is currently in use at many of the leading medical institutions across the country.

About Pathway Medical Technologies, Inc.

Pathway Medical Technologies, Inc. was founded to design market and manufacture medical devices for the treatment of arterial disease. The company's initial focus is treating peripheral arterial disease (PAD) more quickly and effectively than existing technologies. An estimated 12 million people are afflicted by PAD in the U.S. and that number is projected to grow to over 20 million during the next 10 years. The company's Jetstream device allows for a minimally invasive procedure designed to restore circulation in the peripheral arteries by removing both hard and soft diseased tissue. For further information, visit the company's Web site at

Contact Information